Biora Therapeutics Inc
NASDAQ:BIOR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biora Therapeutics Inc
Cash from Operating Activities
Biora Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
Cash from Operating Activities
-$48.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash from Operating Activities
$1.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash from Operating Activities
$10.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
2%
|
|
|
Cigna Corp
NYSE:CI
|
Cash from Operating Activities
$9.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash from Operating Activities
$1.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
5%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Cash from Operating Activities
-$184.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Biora Therapeutics Inc
Glance View
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
See Also
What is Biora Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-48.5m
USD
Based on the financial report for Dec 31, 2023, Biora Therapeutics Inc's Cash from Operating Activities amounts to -48.5m USD.
What is Biora Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
6%
Over the last year, the Cash from Operating Activities growth was 25%. The average annual Cash from Operating Activities growth rates for Biora Therapeutics Inc have been 34% over the past three years , 6% over the past five years .
